news
Zotiraciclib granted Orphan Drug Designation by FDA and EMA
The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.
List view / Grid view
Anti-Cancer Therapeutics
Filter the results
news
Priority Review granted to pemigatinib for treatment of cholangiocarcinoma
The US FDA has awarded pemigatinib Priority Review, after the drug met its primary and secondary endpoints in a Phase II trial.
product
On-demand webinar: Customer Case Study: Adaptimmune Implementing a Paperless QC Micro Laboratory
Learn how Adaptimmune, a leader in developing T cell cancer therapies, implemented Lonza’s MODA™ Solution to manage information in QC micro lab more efficiently.
news
New cancer drugs approvals underpinned by flawed evidence
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.
news
New system delivers drug straight into tumours with fewer side effects
A new drug delivery system disguises chemo-therapeutics as fat in order to destroy tumours.
news
Lynparza has been approved for BRCA-mutated advanced ovarian cancer
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
news
NICE recommends Prevymis on the NHS after re-evaluation
The National Institute for Health and Care Excellence is recommending MSD’s Prevymis (letermovir) within the NHS.
news
First PI3K inhibitor for breast cancer approved by FDA
The US Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets to treat patients with breast cancer.
news
Retail prices on several anti-cancer medications slashed
The retail prices of some anti-cancer drugs have been cut by 87 percent by the drug price control authority in India.
news
Merck recognised with INTERPHEX Exhibitor Award for Best New Product
Merck wins award for first-of-its-kind, single-use tangential flow filtration capsule used in ADC and monoclonal antibody bioprocessing...
Whitepapers/App Notes/Posters
Whitepaper: Analytical criteria in bacterial endotoxin testing using LAL and rFC
This article covers the analytical criteria that apply to Bacterial Endotoxin Testing (BET) using Limulus Amebocyte Lysate (LAL) or recombinant Horseshoe crab Factor C (rFC) for the bioactivity determination of endotoxin in aqueous solutions, such as pharmaceuticals and medical device extracts. It explains the importance of these criteria for accurate…
news
FDA approval for leukaemia non-chemo combination therapy
The FDA has approved the first ever non-chemotherapy combination treatment using ibrutinib and obinutuzumab for the most common form of adult leukaemia...
news
Cancer drug with accelerated approval fails Phase III trial
Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone…
news
European Commission approves prostate cancer treatment Erleada
Erleada (apalutamide) has been approved for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
news
Almac Group extends personalised cancer vaccine production facilities
The Almac Group, a CDMO serving the pharmaceutical and biotech sectors globally, is expanding its Edinburgh Technopole facility to allow scale-up of its personalised cancer vaccine activities...